Sebastien Malinge

Perth, WA, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 38 publications

Menin inhibitors display differential in vitro sensitivity in KMT2A-rearranged infant acute lymphoblastic leukemia.

Menin inhibitors display differential in vitro sensitivity in KMT2A-rearranged infant acute lymphoblastic leukemia.

Journal: Leukemia & lymphoma
Published: February 19, 2026

Pharmacological inhibition of sclerostin protects bone from B-cell acute lymphoblastic leukemia-mediated destruction.

Pharmacological inhibition of sclerostin protects bone from B-cell acute lymphoblastic leukemia-mediated destruction.

Journal: HemaSphere
Published: June 18, 2025

Perspectives on the origin and therapeutic opportunities in Down syndrome-associated leukemia.

Perspectives on the origin and therapeutic opportunities in Down syndrome-associated leukemia.

Journal: Cancer metastasis reviews
Published: April 22, 2025

Preclinical Assessment of Dactinomycin in KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia.

Preclinical Assessment of Dactinomycin in KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia.

Journal: Cancers
Published: December 19, 2024

Childhood leukaemia in Down's syndrome primed by blood-cell bias.

Childhood leukaemia in Down's syndrome primed by blood-cell bias.

Journal: Nature
Published: September 25, 2024

Insights into the Clinical, Biological and Therapeutic Impact of Copy Number Alteration in Cancer.

Insights into the Clinical, Biological and Therapeutic Impact of Copy Number Alteration in Cancer.

Journal: International journal of molecular sciences
Published: May 21, 2024

Targeting osteoclasts for treatment of high-risk B-cell acute lymphoblastic leukemia.

Targeting osteoclasts for treatment of high-risk B-cell acute lymphoblastic leukemia.

Journal: Blood cancer journal
Published: March 29, 2024

The ETO2 transcriptional cofactor maintains acute leukemia by driving a MYB/EP300-dependent stemness program.

The ETO2 transcriptional cofactor maintains acute leukemia by driving a MYB/EP300-dependent stemness program.

Journal: HemaSphere
Published: March 01, 2024

Disruption of cotranscriptional splicing suggests RBM39 is a therapeutic target in acute lymphoblastic leukemia.

Disruption of cotranscriptional splicing suggests RBM39 is a therapeutic target in acute lymphoblastic leukemia.

Journal: Blood
Published: February 12, 2024

Efficacy of DYRK1A inhibitors in novel models of Down syndrome acute lymphoblastic leukemia.

Efficacy of DYRK1A inhibitors in novel models of Down syndrome acute lymphoblastic leukemia.

Journal: Haematologica
Published: September 13, 2023

Down syndrome and leukemia: from basic mechanisms to clinical advances.

Down syndrome and leukemia: from basic mechanisms to clinical advances.

Journal: Haematologica
Published: May 02, 2023

It is more "unbalanced" than you think.

It is more "unbalanced" than you think.

Journal: Blood
Published: March 09, 2023
Showing 1-12 of 38

Last Updated: 09/26/2026